Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
US6034079A · kind A · utility
44Cited by
11References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 23, 1998 |
| Grant date | Mar 7, 2000 |
| Priority date | — |
| Expiry date | Nov 23, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug also is disclosed. The neuropsychiatric disorders include Tourette's syndrome, schizophrenia, depression, bipolar disorder, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.